0000000000393350

AUTHOR

Richard B. Lanman

showing 4 related works from this author

Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor…

2018

9101Background: Approximately 20 % of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. In this study, we have anal...

OncologyCancer Researchmedicine.medical_specialtyLungbusiness.industryDNA sequencingSubtypingInsufficient Tissuemedicine.anatomical_structureOncologyInternal medicineMedicineIn patientStage (cooking)businessGenotypingJournal of Clinical Oncology
researchProduct

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor sampl…

2019

[Background] Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping. [Patients and methods] We conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a h…

MaleLung adenocarcinoma0301 basic medicineOncologyLung NeoplasmsCirculating Tumor DNA0302 clinical medicineco-occurring genomic alterationsGenotypeProspective StudiesNeoplasm MetastasisPrecision MedicineStage (cooking)Prospective cohort studyInsufficient tissueAged 80 and overactionable genomic alterationsHazard ratioHigh-Throughput Nucleotide SequencingDNA NeoplasmGenomicsinsufficient tissueHematologyMiddle AgedActionable genomic alterationsPrognosisSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtydigital next-generation sequencingAdenocarcinoma of Lung03 medical and health sciencesProto-Oncogene ProteinsInternal medicineBiomarkers TumormedicineROS1HumansLung cancerGenotypingAgedDigital next-generation sequencingLungGenome Humanbusiness.industryctDNACo-occurring genomic alterationslung adenocarcinomamedicine.disease030104 developmental biologyMutationbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhib…

2019

[Objectives] Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance.

0301 basic medicineOncologyMaleCancer ResearchLung NeoplasmsTyrosine-kinase inhibitorCirculating Tumor DNAchemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMedicineOsimertinibNeoplasm MetastasisProspective cohort studyAged 80 and overDisease ManagementHigh-Throughput Nucleotide SequencingMiddle AgedOncology030220 oncology & carcinogenesisFemalemedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCabozantinibmedicine.drug_class03 medical and health sciencesInternal medicineROS1Biomarkers TumorHumansLung cancerProtein Kinase InhibitorsAgedNeoplasm StagingDigital next-generation sequencingTKI resistanceCrizotinibbusiness.industryOncogene-driven NSCLCOncogenesctDNAmedicine.diseaseLorlatinibrespiratory tract diseases030104 developmental biologychemistryDrug Resistance NeoplasmMutationbusinessOsimertinib
researchProduct

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

2020

Abstract HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of m…

0301 basic medicineFulvestrantCombination therapybusiness.industryEstrogen receptormedicine.diseaseMetastatic breast cancer03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisNeratinibmedicineCancer researchSignal transductionskin and connective tissue diseasesbusinessmedicine.drugCancer Discovery
researchProduct